Total
0
Shares
Zoono Group (ASX:ZNO) - Managing Director & CEO, Paul Hyslop - The Market Herald
Managing Director & CEO, Paul Hyslop
Source: Zoono Group
  • Zoono Group's (ZNO) Z-71 Microbe Shield surface sanitiser has been successfully tested against COVID-19
  • Laboratory tests show the product is more than 99.99 per cent effective against the virus
  • Z-71 is the same technology used in the company's hand sanitiser
  • Zoono's products are known to protect humans against a variety of viruses for up to 30 days on surfaces and 24 hours on hands
  • Zoono is up 9.26 per cent on the market this morning, trading at $1.77 per share

Zoono Group's (ZNO) Z-71 Microbe Shield surface sanitiser has been successfully tested against the recent coronavirus (COVIOD-19).

Laboratory tests show the product is more than 99.99 per cent effective against the virus.

COVID-19 has become a global concern and has been shown to survive on surfaces for up to nine days. Zoono products have been successfully tested against a variety of pathogens for up to 30 days on surfaces and 24 hours on hands.

Z-71 was previously tested against bovine coronavirus, however, this latest strain required new testing.

The company conducted two separate tests to EN Standard 14476:2013+A2:2019 for chemical disinfectants and antiseptics.

EN14476 is the European Standard that applies to products within the medical area, this includes hygienic hand rubs, hygienic hand wash, instrument disinfection by immersion, surface disinfection by wiping, spraying, flooding and others.

Z-71 Microbe Shield is the same technology used in the company's hand sanitisers.

"Zoono is very pleased with the results which further demonstrates the ability of the Zoono technology to be part of the solution to prevent and protect against the spread of the COVID19 Virus," the company told the market.

Zoono is up 9.26 per cent on the market this morning, trading at $1.77 per share at 11:31 am AEDT.


Subscribe


ZNO by the numbers
More From The Market Herald
Imagion Biosystems (ASX:IBX) - CEO & Executive Chairman, Bob Proulx - The Market Herald

" Imagion Biosystems (ASX:IBX) updates market on December quarter

Imagion Biosystems (IBX) has updated the market regarding its activities and cash flow during the December quarter.
Imugene (ASX:IMU) - CEO, Leslie Chong - The Market Herald

" Imugene (ASX:IMU) proceeds to higher dose of PD1-VAXX in clinical trial

Imugene (IMU) has announced the Cohort Review Committee (CRC) has confirmed its phase one clinical trial for PD1-Vaxx will proceed to the second
AnteoTech (ASX:ADO) - CEO, Derek Thomson - The Market Herald

" AnteoTech (ASX:ADO) wins $1.4M grant for COVID-19 test development

Chemistry company AnteoTech (ADO) has been awarded a $1.4 million grant from the Queensland State Government.
Fiji Kava (ASX:FIJ) appoints Jack Lowenstein as Non-Executive Director

" Fiji Kava (ASX:FIJ) increases revenue by 94pc in December quarter

Fiji Kava (FIJ) has recorded some strong results in its latest quarterly report, including a 94 per cent increase in revenue.